MicroSmart Completes Tens of Millions RMB Pre-A Financing to Advance Clinical Innovation in Fluorescence Molecular Imaging

VCBeat has learned that Jinan Shinevia Intelligent Technology Co., Ltd. (hereinafter referred to as “Shinevia”), a leading domestic company in specialized light imaging, recently completed a pre-A financing round worth tens of millions of yuan. The round was led by GT Venture Capital, with participation from Zhenghai Investment and others.。The proceeds from this round of financing will be used for the research and development and registration of new products, academic marketing promotion, and team expansion.

ShineVia, established in 2017 with its management headquarters in Shanghai, has set up functional centers for R&D, production, and sales in Hangzhou, Changsha, and Jinan, respectively. The company boasts a globally leading specialized optical imaging technology platform, featuring its independently developed, pioneering picomolar-level ultra-high-sensitivity image detector, which ranks among the best worldwide. In 2020, ShineVia secured angel-round investment from Luxin Venture Capital.

Currently, the company has secured more than 30 relevant patents. Its patent portfolio in the field of special light imaging ranks among the top three globally. The company has established a product lineup comprising fluorescence navigation devices for thyroid and parathyroid surgery, fluorescence navigation devices for minimally invasive surgery, and disposable surgical consumables, thereby creating a “device + consumables” commercial closed loop. Notably, products such as the parathyroid imaging system and the triple-tracer fluorescence endoscopy system are first-of-their-kind innovations in China.ShineVia is one of the few companies worldwide that has mastered autofluorescence imaging technology and successfully achieved commercialization.

Regarding this financing round, Yang Cong, founder of Shinevia, stated:We extend our heartfelt gratitude to both new and existing shareholders for their continued attention and recognition of Shinevia. Since 2014, Shinevia’s founding team has been dedicated to the independent research and development of specialized optical imaging technologies. Adhering consistently to actual clinical needs, we have enhanced patient treatment outcomes and quality of life, optimized healthcare resource utilization, and achieved successful R&D breakthroughs and commercialization of multiple internationally leading technologies. Throughout this journey, the company has been privileged to receive steadfast support from professional medical teams, scientific research groups, investment institutions, and friends across all sectors of society. We remain committed to our original mission, living up to the trust placed in us, and pressing forward without pause. Against the backdrop of the great rejuvenation of the Chinese nation, China’s innovative medical enterprises are poised to flourish. Shinevia is determined to join the global forefront, striving to become a technological revolutionary, a rule-maker, and an industry leader. We are devoted to exploring the vast frontiers of technological innovation, safeguarding human health and hygiene.

Fei Zhengxian, Investment Director at GT Ventures, stated:Shinevia possesses globally leading reserves in fluorescent molecular imaging technology and has a rich pipeline layout. The company was the first in China to apply autofluorescence technology for intraoperative parathyroid protection, and its domestically pioneered autofluorescence parathyroid identification system has been approved for market launch and is generating sales. Furthermore, Shinevia’s picomolar-level ultra-sensitive fluorescence detectors and triple-tracer technologies are poised to deliver greater patient benefits across fields such as rigid fluorescent endoscopy, flexible fluorescent endoscopy, and single-use fluorescent endoscopes. Although the domestic endoscopy market holds immense potential, it has long been monopolized by multinational corporations. With the introduction of supportive policies for domestically produced medical devices, several Chinese innovative enterprises have begun to emerge. GT Venture Capital believes that Shinevia’s team has demonstrated integrated capabilities in R&D, production, and sales. By continuing to leverage its strong commercialization execution, Shinevia is well-positioned to break through in this market and become an industry leader.

Wang Tao, General Manager of Zhenghai Investment, stated:Shinevia is a technology company possessing globally leading fluorescence molecular imaging technologies. It pioneered the original development of a picomolar-level ultra-high-sensitivity image detector and introduced China’s first autofluorescence imaging device for parathyroid glands, effectively improving intraoperative parathyroid detection rates and filling a domestic gap. Additionally, it launched the world’s first fluorescent endoscope with triple-tracing capabilities—autofluorescence, ICG, and methylene blue—offering differentiated competitive advantages. Its products have gained recognition from numerous hospital experts across China, positioning the company to potentially become a leading enterprise in the field of fluorescence molecular imaging. We remain optimistic about the company’s future prospects.

Mr. Chen Lei, Chairman of Luxin Venture Capital and an angel investor, stated:Luxin Venture Capital has always placed great emphasis on its investment strategy in the field of innovative medical devices. Fluorescence molecular imaging technology represents a key direction in the development of modern medical imaging, offering broad prospects for clinical application. Jinan Shinevia Intelligent Technology Co., Ltd. is a leader in this field, boasting outstanding innovation and technology commercialization capabilities. Its multiple self-developed products hold significant competitive advantages in their respective niche markets and have been widely applied in thyroid and parathyroid surgery as well as minimally invasive surgery, indicating substantial market potential. The management team is diligent, pragmatic, and enterprising. We remain optimistic about Shinevia’s future and hope that it will make greater contributions to the advancement of fluorescence molecular imaging technology in China.

GT Ventures focuses on globally leading innovative drugs and medical technology sectors. It made early-stage investments in Oxford Nanopore Technology, Immunocore, Exscientia, Auris Health (acquired by Johnson & Johnson), and Zap Surgical, among others. In China, it has incubated the AI-driven innovative drug platform Pailong Biopharma and the innovative medical device platform Painova Medical. Driven by the organic integration of technological advancement and market application, GT Ventures is committed to delivering greater benefits to patients worldwide from an investor’s perspective.

Zhenghai Investment, established in 2016, is an investment firm with a strong industrial background. Its controlling shareholder is Zhenghai Group, which boasts over three decades of expertise in industrial operations across multiple manufacturing sectors and owns two listed companies: Zhenghai Magnetic Material (300224.SZ) and Zhenghai Biologics (300653.SZ). Since its inception, Zhenghai Investment has initiated and established multiple equity investment funds, achieving numerous successful investments in fields such as advanced manufacturing and medical devices. Upholding the business philosophy of “striving for human well-being and achieving win-win outcomes with partners,” the company is committed to collaborating with more startups for mutual growth and development.

Luxin Venture Capital is the largest professional venture capital firm in Shandong Province and one of the most influential in China, controlled by Shandong Luxin Investment Holding Group Co., Ltd. It is the first venture capital institution listed on China’s capital market (stock code: 600783.SH). Over the past two decades since its establishment, the company has managed and operated more than 40 funds with a total scale of RMB 27 billion, covering sub-sectors such as healthcare, military-civilian integration, advanced manufacturing, electronic information, new energy, and new materials. It has invested in over 30 companies listed both domestically and internationally. In the healthcare sector, it has successively invested in a number of outstanding enterprises, including 3D Medicines (Sailuodi Aitis), Silicon-Based Bionics, Abclonal, Weimai Medical, and RemeGen.